A study published in the journal, Osteoporosis International, discovered a higher prevalence of comorbidities in patients with lower levels of vitamin D compared to patients with higher levels.
In order to be included in the analysis, the participant’s must not have been admitted to the hospital for care. In addition, their vitamin D levels had to be above 20 ng/ml (50 nmol/l) and below 50 ng/ml (125 nmol/l).
A total of 529 participants were included in the analysis. All individuals were divided into two groups: group 1 had 25(OH)D ≥ 20 ng/ml and < 30 ng/ml (≥50 nmol/l and <75 nmol/l); and group 2 had 25(OH)D ≥30 and ≤ 50 ng/ml (≥75 nmol/l and <125 nmol/l). Medical records for all participants were evaluated and notable data, including the presence of comorbidities, were used for the analysis.
This is what the researchers found:
The researchers concluded:
“Outpatients of a tertiary hospital with 25OHD ≥ 20 and < 30 ng/mL had higher prevalence of comorbidities compared to those with levels ≥ 30 and ≤ 50 ng/mL, suggesting that for this specific population 25OHD within the latter range would be more appropriate”